MicroGenDX Press Releases

 
September 16, 2021
MicroGenDX News

Dr. J. Curtis Nickel Urinary Microbiome Study Using MicroGenDX NGS Indicates Microbial Diversity Varies by Age and Gender

Dr. J. Curtis Nickel, with the help of MicroGenDX, has completed a study to help understand the implications of Next-Generation DNA Sequencing (NGS) in the diagnosis and treatment of Urinary Tract Infections (UTIs) and other inflammatory urological conditions.
September 10, 2021
MicroGenDX News

MicroGenDX Resolves Dispute with AdventHealth over COVID-19 Testing Services

ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics (MicroGenDX) is pleased to announce that it has resolved a dispute with AdventHealth concerning Covid-19 testing services that were provided to AdventHealth during the height of the global pandemic in May of 2020.
September 1, 2021
MicroGenDX News

MicroGenDX Announces Acquisition of RTL Genomics to Advance Primary Research in DNA Sequencing

ORLANDO, Fla., Sep 1, 2021 /PRNewswire/ — MicroGen Diagnostics, the industry leader in providing Next-Generation DNA Sequencing (NGS) for clinical diagnostics, has acquired its RTL Genomics partner lab to expand expertise and capacity in non-clinical primary research.
May 25, 2021
MicroGenDX News

MicroGenDX Announces OrthoKEY® Infection Diagnosis and Management for Periprosthetic Joint Infection

ORLANDO, Fla., May 24, 2021 /PRNewswire/ — MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, has introduced OrthoKEY, an innovative approach to address current clinical shortcomings in the diagnosis of orthopedic infections. OrthoKEY brings accuracy, sensitivity, timeliness, and affordability to PJI diagnostics and management for the clinic and operating room.
May 24, 2021
MicroGenDX News

MicroGenDX is Introducing PerioDX, the First Commercially Available Saliva-Based qPCR+NGS Test for Oral Health

MicroGen Diagnostics, the industry leader in providing next-generation DNA sequencing (NGS) for clinical diagnostics, announces its entry into oral microbial diagnostics with the PerioDX test. PerioDX is the first commercially available saliva-based periodontal test to combine quantitative polymerase chain reaction (qPCR) and NGS technology for comprehensive DNA diagnostic results. PerioDX identifies 17 antibiotic resistance genes and all clinically relevant microbes in a sample,1 thereby assisting clinicians both with treatment choices and promoting antimicrobial stewardship.
 
Translate »
Shopping Cart
There are no products in the cart!
Continue Shopping
0